Sökning: id:"swepub:oai:prod.swepub.kib.ki.se:148249261" >
Comparison of clini...
Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort
-
Peakman, G (författare)
-
Russell, LL (författare)
-
Convery, RS (författare)
-
visa fler...
-
Nicholas, JM (författare)
-
Van Swieten, JC (författare)
-
Jiskoot, LC (författare)
-
Moreno, F (författare)
-
Sanchez-Valle, R (författare)
-
Laforce, R (författare)
-
- Graff, C (författare)
- Karolinska Institutet
-
Masellis, M (författare)
-
Tartaglia, MC (författare)
-
Rowe, JB (författare)
-
Borroni, B (författare)
-
Finger, E (författare)
-
Synofzik, M (författare)
-
Galimberti, D (författare)
-
Vandenberghe, R (författare)
-
de Mendonca, A (författare)
-
Butler, CR (författare)
-
Gerhard, A (författare)
-
Ducharme, S (författare)
-
Le Ber, I (författare)
-
Tagliavini, F (författare)
-
Santana, I (författare)
-
Pasquier, F (författare)
-
Levin, J (författare)
-
Danek, A (författare)
-
Otto, M (författare)
-
Sorbi, S (författare)
-
Rohrer, JD (författare)
-
visa färre...
-
(creator_code:org_t)
- 2021-08-05
- 2022
- Engelska.
-
Ingår i: Journal of neurology, neurosurgery, and psychiatry. - : BMJ. - 1468-330X .- 0022-3050. ; 93:2, s. 158-168
- Relaterad länk:
-
https://jnnp.bmj.com...
-
visa fler...
-
http://kipublication...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Therapeutic trials are now underway in genetic forms of frontotemporal dementia (FTD) but clinical outcome measures are limited. The two most commonly used measures, the Clinical Dementia Rating (CDR)+National Alzheimer’s Disease Coordinating Center (NACC) Frontotemporal Lobar Degeneration (FTLD) and the FTD Rating Scale (FRS), have yet to be compared in detail in the genetic forms of FTD.MethodsThe CDR+NACC FTLD and FRS were assessed cross-sectionally in 725 consecutively recruited participants from the Genetic FTD Initiative: 457 mutation carriers (77 microtubule-associated protein tau (MAPT), 187 GRN, 193 C9orf72) and 268 family members without mutations (non-carrier control group). 231 mutation carriers (51 MAPT, 92 GRN, 88 C9orf72) and 145 non-carriers had available longitudinal data at a follow-up time point.ResultsCross-sectionally, the mean FRS score was lower in all genetic groups compared with controls: GRN mutation carriers mean 83.4 (SD 27.0), MAPT mutation carriers 78.2 (28.8), C9orf72 mutation carriers 71.0 (34.0), controls 96.2 (7.7), p<0.001 for all comparisons, while the mean CDR+NACC FTLD Sum of Boxes was significantly higher in all genetic groups: GRN mutation carriers mean 2.6 (5.2), MAPT mutation carriers 3.2 (5.6), C9orf72 mutation carriers 4.2 (6.2), controls 0.2 (0.6), p<0.001 for all comparisons. Mean FRS score decreased and CDR+NACC FTLD Sum of Boxes increased with increasing disease severity within each individual genetic group. FRS and CDR+NACC FTLD Sum of Boxes scores were strongly negatively correlated across all mutation carriers (rs=−0.77, p<0.001) and within each genetic group (rs=−0.67 to −0.81, p<0.001 in each group). Nonetheless, discrepancies in disease staging were seen between the scales, and with each scale and clinician-judged symptomatic status. Longitudinally, annualised change in both FRS and CDR+NACC FTLD Sum of Boxes scores initially increased with disease severity level before decreasing in those with the most severe disease: controls −0.1 (6.0) for FRS, −0.1 (0.4) for CDR+NACC FTLD Sum of Boxes, asymptomatic mutation carriers −0.5 (8.2), 0.2 (0.9), prodromal disease −2.3 (9.9), 0.6 (2.7), mild disease −10.2 (18.6), 3.0 (4.1), moderate disease −9.6 (16.6), 4.4 (4.0), severe disease −2.7 (8.3), 1.7 (3.3). Sample sizes were calculated for a trial of prodromal mutation carriers: over 180 participants per arm would be needed to detect a moderate sized effect (30%) for both outcome measures, with sample sizes lower for the FRS.ConclusionsBoth the FRS and CDR+NACC FTLD measure disease severity in genetic FTD mutation carriers throughout the timeline of their disease, although the FRS may be preferable as an outcome measure. However, neither address a number of key symptoms in the FTD spectrum, for example, motor and neuropsychiatric deficits, which future scales will need to incorporate.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Peakman, G
-
Russell, LL
-
Convery, RS
-
Nicholas, JM
-
Van Swieten, JC
-
Jiskoot, LC
-
visa fler...
-
Moreno, F
-
Sanchez-Valle, R
-
Laforce, R
-
Graff, C
-
Masellis, M
-
Tartaglia, MC
-
Rowe, JB
-
Borroni, B
-
Finger, E
-
Synofzik, M
-
Galimberti, D
-
Vandenberghe, R
-
de Mendonca, A
-
Butler, CR
-
Gerhard, A
-
Ducharme, S
-
Le Ber, I
-
Tagliavini, F
-
Santana, I
-
Pasquier, F
-
Levin, J
-
Danek, A
-
Otto, M
-
Sorbi, S
-
Rohrer, JD
-
visa färre...
- Artiklar i publikationen
-
Journal of neuro ...
- Av lärosätet
-
Karolinska Institutet